IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3340
Positioning
Market Dominance
Services
Healthcare
$2M
Siu Wing Fung Alfred
Detailed business profile pending verification.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = NIVF ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$YALA Yalla Group Ltd | 75 | 89 | 99 | 80 | - | - | 21.3% | 18.6% | 64.5% | 35.7% | 39.5% | 6.5% | 0.0% | 0.0x | $644M | VS | |
$GRVY GRAVITY Co., Ltd. | 75 | 82 | 96 | 71 | - | - | 15.4% | 12.6% | 38.7% | 17.1% | 17.0% | -39.7% | 0.0% | 0.0x | $439M | VS | |
$ISSC INNOVATIVE SOLUTIONS & SUPPORT INC | 73 | 81 | 88 | 94 | 25.0x | 14.1x | 28.1% | 16.8% | 48.1% | 23.8% | 18.5% | 78.6% | 0.0% | 37.0x | $220M | VS | |
$AER AerCap Holdings N.V. | 72 | 60 | 87 | 84 | - | - | 12.4% | 2.9% | 100.0% | 28.2% | 26.2% | 5.5% | 0.8% | 264.0x | $19.4B | VS | |
$HCSG HEALTHCARE SERVICES GROUP INC | 72 | 74 | 88 | 88 | 7.1x | 6.1x | 28.9% | 20.8% | 20.8% | 9.9% | 9.3% | 8.5% | 0.0% | 1.0x | $1.2B | VS | |
$LQDT LIQUIDITY SERVICES INC | 72 | 90 | 88 | 68 | 24.9x | 14.3x | 14.6% | 7.8% | 43.8% | 7.4% | 5.9% | 31.2% | 0.0% | 0.0x | $857M | VS | |
$TRTNpA Triton International Ltd | 71 | 70 | 89 | 70 | - | 1.7x | 18.0% | 4.6% | 97.3% | 52.2% | 32.7% | -3.4% | 0.0% | 271.0x | $8.0B | VS | |
$EDU New Oriental Education & Technology Group Inc. | 71 | 83 | 52 | 77 | - | - | 9.4% | 4.9% | 55.5% | 8.7% | 7.7% | 13.6% | 1.3% | 7.0x | $78.0B | VS | |
$NTES NetEase, Inc. | 71 | 88 | 93 | 68 | - | - | 22.1% | 15.6% | 62.5% | 28.1% | 28.7% | -1.0% | 2.8% | 9.0x | $56.6B | VS | |
$UTI UNIVERSAL TECHNICAL INSTITUTE INC | 70 | 86 | 86 | 72 | 43.2x | 16.0x | 21.4% | 8.0% | 100.0% | 10.0% | 7.5% | 14.1% | 0.0% | 27.0x | $1.8B | VS | |
$NIVF NewGenIvf Group Ltd | 42 | 46 | 36 | 26 | - | 48.1x | -113.3% | -111.7% | 33.6% | -21.4% | -18.4% | 5.8% | 0.0% | - | $2M | ||
| SECTOR BENCH | - | - | - | - | - | 23.7x | 11.7x | 5.3% | 1.9% | 59.6% | 3.5% | 2.3% | 7.8% | 0.0% | 0.3x | - | REF |
NewGenIvf Group Ltd (NIVF) receives a "Reduce" rating with a composite score of 41.6/100. It ranks #3340 out of 7,333 stocks in our coverage universe and carries a 2-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Direct cash return
Siu Wing Fung Alfred
Chief Executive Officer
46
44
15
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for NIVF
Lagging peers — losers tend to keep underperforming
Fair valuation relative to peers
Average quality profile
High volatility — wider range of outcomes increases timing risk
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Services sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for NIVF.
View All RatingsInsufficient data for Financial Analysis
| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 46 | 48 | -2NEUTRAL |
| MOMENTUM | 26 | 19 | +7ALPHA |
| VALUATION | 36 | 30 | +6ALPHA |
| INVESTMENT | 44 | 77 | -33DRAG |
| STABILITY | 15 | 7 | +8ALPHA |
| SHORT INT | 51 | 55 | -4NEUTRAL |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC -37.4% vs WACC 5.3% (spread -42.6%)
GM 34% vs sector 60%, OM -21% vs sector 4%
Capital turnover 2.21x
Rev growth 6%, 2yr history
Interest coverage N/A, Net debt/EBITDA 143.0x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
NewGenIvf Group Ltd receives a Reduce rating from our analysis, with a composite score of 41.6/100 and 2 out of 5 stars, ranking #3340 out of 7,333 stocks. NIVF's factor profile shows weakness across multiple dimensions, suggesting the stock may underperform going forward. Existing holders may want to consider trimming positions or tightening stop-losses.
With a quality score of 46/100, NIVF shows adequate but unremarkable business quality. The company reports a return on equity of -113.3% (sector avg: 5.3%), gross margins of 33.6% (sector avg: 59.6%), net margins of -18.4% (sector avg: 2.3%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
With a value score of 36/100, NIVF appears somewhat expensive relative to its fundamentals. Key valuation metrics include an EV/EBITDA of 48.06x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
With an investment score of 44/100, NIVF exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of 5.8% vs. a sector average of 7.8% and a return on assets of -111.7% (sector: 1.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
NewGenIvf Group Ltd is experiencing notably weak momentum with a score of just 26/100. The stock has underperformed its peers and is trending below major moving averages. Revenue growth stands at 5.8% year-over-year, while a beta of 1.01 reflects its sensitivity to broader market moves. While deep momentum weakness can occasionally present value opportunities, it often reflects deteriorating fundamentals or structural headwinds that may persist.
NewGenIvf Group Ltd registers a low stability score of 15/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 1.01. Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.
The short interest score of 51/100 for NIVF suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include micro-cap liquidity risk. With a $2M market cap (micro-cap), NewGenIvf Group Ltd may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
NewGenIvf Group Ltd is a micro-cap company in the Services sector, ranked #0 of 50 in its sector (100th percentile) and #3340 of 7,333 overall (54th percentile). Key comparisons include ROE of -113.3% trailing the 5.3% sector median and operating margins of -21.4% below the 3.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Services peers.
While NIVF currently exhibits a REDUCE profile, superior opportunities exist within the SERVICES sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Services Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Stability (15) would have the largest impact on the composite score.
EV/EBITDA 310% ABOVE SECTOR MEDIAN
ROE 2233% BELOW SECTOR MEDIAN
Gross Margin 44% BELOW SECTOR MEDIAN
AUDIT DATA AS OF DEC 31, 2024 (Q3 FY2024)
We rate NewGenIvf Group Ltd (NIVF) as a Reduce with a composite score of 41.6/100 at a current price of $0.83. The quantitative profile shows weakness across multiple dimensions, suggesting limited upside potential and elevated risk of underperformance relative to peers over the next 12 months.
The rating is primarily driven by strength in quality (46th percentile) and investment (44th percentile), which together account for the majority of the composite score. Offsetting weakness in stability (15th percentile) and momentum (26th percentile) tempers our overall conviction. We assign a No Moat rating (32/100), High uncertainty, and Poor capital allocation.
Key items to watch: momentum to confirm whether the current price trend has legs; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
NewGenIvf Group Ltd holds a top-quartile position (#0 of 50) within the Services sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 41.6/100 places it at rank #3340 in our full 7,333-stock universe. At $2M in market capitalization, NewGenIvf Group Ltd is a small-cap player in the Services space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 6%, though momentum at the 26th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 34% (-26.0pp vs sector) narrow to operating margins of -21% (-24.9pp vs sector) and net margins of -18.4%, yielding a gross-to-net conversion rate of -55%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $0.83, NewGenIvf Group Ltd is trading at a premium to fundamental value. Our value factor score of 36/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.
The stock currently trades at EV/EBITDA of 48.1x (at a premium), P/S of 0.0x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
The stock may offer contrarian value if near-term headwinds prove transitory — the current weakness in factor scores may reverse if business fundamentals stabilize.
The Reduce rating (composite 41.6/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Thin net margins of -18.4% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
Weak momentum (26th percentile) suggests institutional selling pressure and unfavorable technical dynamics that may persist.
We assign a High uncertainty rating to NewGenIvf Group Ltd. Key risk factors include current negative profitability (net margin -18.4%), below-average price stability (15th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -18.4%); below-average price stability (15th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 15th percentile and quality factor at the 46th percentile provide a quantitative summary of the overall risk landscape.
We identify limited risk mitigants at this time, which contributes to our high uncertainty assessment. Investors should monitor for improvement in balance sheet metrics, margin stability, and business predictability that could warrant a downgrade in our risk assessment over time.
We rate NewGenIvf Group Ltd's capital allocation as Poor. Key concerns include low returns on equity (-113.3%), negative profitability, weak asset returns (ROA -111.7%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — NewGenIvf Group Ltd significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, NewGenIvf Group Ltd receives a Reduce rating with a composite score of 41.6/100 (rank #3340 of 7,333). Our quantitative framework assigns a No Moat (32/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 33/100.
Our analysis does not support a constructive view on NewGenIvf Group Ltd at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign NewGenIvf Group Ltd a meaningful economic moat, scoring 32/100 on our composite assessment. The ROIC-WACC spread of -42.6% is the primary signal of economic value creation. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, reinvestment efficiency, reached only 16.9/20.
The strongest moat sources are reinvestment efficiency (16.9/20) and margin superiority (6.1/20). Capital turnover 2.21x. GM 34% vs sector 60%, OM -21% vs sector 4%. These pillars form the core of NewGenIvf Group Ltd's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (0/20) and financial resilience (3.3/20). ROIC -37.4% vs WACC 5.3% (spread -42.6%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect NewGenIvf Group Ltd's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include moderate revenue growth of 6%. The margin cascade from 34% gross to -21% operating to -18.4% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality is adequate though not exceptional, with the quality factor at the 46th percentile.
The margin profile shows gross margins of 34%, operating margins of -21%, net margins of -18.4%. Return metrics include ROE of -113.3% and ROA of -111.7%. Relative to the Services sector, gross margins are 26.0 percentage points below the sector median of 60%, and ROE of -113.3% compares to a sector median of 5.3%.
The balance sheet reflects revenue growth of 6%. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
Management reiterates strong confidence in NewGen’s long-term fundamentals and disciplined capital allocation strategyBANGKOK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (Nasdaq: NIVF) (“NewGen” or the “Company”), a tech-forward, diversified, multi-jurisdictional entity transforming industries through innovative solutions across real estate development, digital asset management and reproductive health solutions, today announced that it intends to execute its previously authorized
Strategic Move to Unlock Further Value and Accelerate Project Momentum with Planned Fundraising and Upcoming Presale LaunchBANGKOK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- NewGenIVF Group Limited (“NewGen” or the “Company,” NASDAQ: NIVF), a technology-driven company building a diversified ecosystem across fertility technology, digital assets, and real estate development, today announced its intention to exercise an option under its joint venture agreement (“JVA”) with BNW Real Estate Development LLC (
NewGenIvf Group acquired advanced cytometry intellectual property, receiving a valuation of $17.9 million, which boosts the company's net asset value and marks a strategic transition from traditional IVF services to a technology-driven service provider.
NewGenIVF, a fertility services provider in Asia, has terminated its proposed reverse merger transaction with European Wellness Investment Holdings Limited due to the latter's failure to deliver required financial statements by the deadline.
NewGenIvf Group Limited (NIVF) provided an update on its proposed reverse merger with European Wellness Investment Holdings Limited (EWIHL) and the completion of its acquisition of MicroSort Reproductive Technology. The company is evaluating strategic acquisition opportunities to align with its growth strategy.